Global mRNA Platform Industry

Abstract: The ongoing Covid-19 pandemic has highlighted the potential for mRNA therapies. The mRNA technology has experienced decades of research efforts from scientists and various biotechnology companies.

New York, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global mRNA Platform Industry" - https://www.reportlinker.com/p06156075/?utm_source=GNW
Discovered in the 1960s as an option to convert DNA codes into proteins, mRNA took several decades to emerge as promising therapeutic modality for various medical conditions. mRNA medicines make use of the usual biological processes to extract proteins and create the required therapeutic effect, due to which the treatment of several diseases that cannot be achieved using current technologies is made easy. mRNA therapeutics have gained major attention following the development of new synthesis as well as delivery approaches. The advances in the generation, purification and cellular delivery of RNA have widened the scope of RNA-based therapeutics for a broad array of applications. The technology is marked by its compelling advantages over traditional methods in terms of turnaround times, production speed and cost savings. Various clinical and preclinical studies have indicated promising results for protein replacement therapies, prevention of infectious diseases, tumor immunotherapy and cancer vaccines. In the historic global race to develop a vaccine, mRNA based Covid-19 vaccine from Moderna and Pfizer stand out as frontrunners. The unique characteristics of mRNA has made it of great interest to vaccine developers. While traditional vaccines have used live or inactivated pathogens to elicit an immune response, mRNA is responsible for cellular processes, building structures, regulating functions, and building structural components. mRNA vaccines work by introducing a part of mRNA that reacts to the viral protein. It accelerates production of antibodies and trains the immune system to recognize the virus in the future, thereby offering protection. Essentially a chemical process, production of mRNA vaccines eliminates the need for growing proteins or viruses, a key reason why vaccines by Moderna and Pfizer/BioNTech quickly reached human trials. For instance, Moderna`s vaccine was created in just six weeks. Securing approval for emergency use, the two vaccines demonstrated around 95% efficacy in eliciting immune response against the COVID-19 virus during clinical trials.

Beyond Covid-19, mRNA-based therapies hold promise for combatting cancer, infectious diseases such as malaria and flu, and rare genetic diseases. Results from early animal testing demonstrates the ability of mRNA-based therapeutics to provide protection against viruses such as influenza, Zika and rabies. With the effectiveness of mRNA vaccines against Covid-19, there is heightened research interest in pursuing mRNA platform for treating infectious diseases, for example, BioNTech is preparing to launch the first vaccine for malaria based on mRNA technology with plans to conduct clinical testing by the end of 2022. Similarly, Moderna also announced plans to conduct human trials for an HIV vaccine. Currently, of the total 44 ongoing clinical trials of mRNA vaccines, 23 of them are aimed at infectious diseases. Cancer research has used mRNA platform to trigger the immune system to target specific cancer cells. Currently, there are many clinical trials underway utilizing mRNA vaccines for various cancers. Most of the mRNA cancer vaccine trials are targeting tumors such as melanoma and kidney cancer. An mRNA vaccine could be custom-made to match the genetic signature of an individual`s cancer. This personalized mRNA vaccine could be used following surgery to program the immune system to search out and destroy any residual cancer cells, and thus prevent the cancer from recurring. For instance, the pipelines of Moderna and BioNTech include drug trials for treating cancers of the brain, breast, prostate, pancreas, lung, skin and other tissues. The mRNA vaccines market is projected to receive notable contribution from the cancer segment that is estimated to claim the leading revenue share over the coming years. The segment`s growth is augmented by increasing incidence of cancer. The condition remains one of the major causes of mortalities globally, with the number of new cases annually exceeding 23.6 million by the year 2030.

mRNA is also being pursued to aid in rapid development of drugs for rare diseases. Recent advancements in the structural composition of mRNA have led the scientific community to swiftly embrace it as a new drug to deliver missing genes to organs. The pipelines of Moderna, CureVac and BioNTech, three major biopharmaceutical companies, cover heart diseases, metabolic diseases and immunomodulators for applications in immuno-oncology. The introduction of synthetic mRNA into human cells opens scope for a replacement therapeutic option for conditions known for defective or inadequate synthesis of key proteins. The approach holds significant potential over protein replacement and gene therapies owing to its lower risk, affordability and less frequent dosage. mRNA can be used as protein replacement therapy to treat diseases caused by a lack of protein, or by defective proteins. Many mRNA-based protein replacement therapies are under development for the heart, lungs and liver. For example, Cardior Pharmaceuticals, a Germany-based biotechnology company, is working on RNA drugs for treatment of heart failure. Translate Bio developed a protein replacement therapy for cystic fibrosis, which is currently undergoing Phase 1/2 clinical trial. In addition, mRNA is being explored as potential alternative to the gene therapy for treatment of intractable medical conditions like sickle cell disease. Increased scientific interest and funding brought on by the pandemic is expected to further boost advancements in mRNA vaccine and therapeutics technologies. The widespread recognition is leading to new uses of mRNA being developed and approved.
Select Competitors (Total 96 Featured)

• BioNTech AG

• CureVac AG

• Dicerna Pharmaceuticals

• eTheRNA Immunotherapies

• ethris GmbH

• In-Cell-Art

• Moderna, Inc.

• Regulus Therapeutics

• Sangamo Therapeutics, Inc.

• Tiba Biotech

• Translate Bio, Inc.

Read the full report: https://www.reportlinker.com/p06156075/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Impact of Covid-19 and a Looming Global Recession
The Race between the Virus & Vaccines Intensifies
Effectiveness of Vaccinations
Covid-19 Vaccine Shortages Hit Global Supply Initiative
Dosing Interval Adjustment to Expand Coverage
Global COVID-19 Vaccine Inequity
Impact of Vaccine Inequity on the Labor Market
mRNA - A CONCEPTUAL UNDERSTANDING
mRNA: A New Approach to Medicine
Long Wait & Scientific Breakthroughs
mRNA Vaccines - An Introduction
With Unparalleled Turnaround Time, mRNA Platform Adds
Revolutionary Dimension to Vaccine Development
mRNA: Making Cells Act as Vaccine Factory
mRNA Vaccine Approvals
A Comparison of Pfizer, Moderna Vis-a-vis AstraZeneca and J&J
Vaccine
mRNA Vaccines: Advantages
Traditional Vs. mRNA Vaccines: Key Differences
Traditional Vs. mRNA Vaccines: The Development Process
How mRNA Vaccine Works & Earlier Testing Efforts
mRNA Vaccines: Safety Quotient
Other Notable Efforts Centered on mRNA Technology
Overcoming Challenges
As Serious Candidate, mRNA Technology Warrants Attention from
Scientific Community
GLOBAL MARKET OVERVIEW
Global mRNA Vaccines Market on a Dynamic Growth Track
Riding COVID-19 Wave, mRNA Vaccines Take Center Stage & See
Exciting Times Ahead
COVID-19 mRNA Vaccine Approval Details
COVID-19 Funding Details of Moderna and Pfizer Vaccine
EXHIBIT 1: Production Capacity of mRNA Frontrunners in Millions
of Doses for 2021
mRNA Vaccines Could Vanquish Cancer and Other Diseases, Cancer
Segment to Make Major Contribution to Global mRNA Vaccines
Market
The US Holds Leading Position, while Asia-Pacific Exhibits
Lucrative Growth in mRNA Vaccines Market
Faster, Effective and Cheaper: Adaptability of mRNA Vaccine
Unleashes Potential Utility for Developing Nations
The East Falls behind the West in Embracing the Revolutionary
mRNA Technology for Developing Vaccines to Fight against
COVID-19
COVID-19 Pandemic: An Eventful Year for RNA
COVID-19?s Impact on Vaccine Development - A Transformative
Shift to mRNA vaccines
mRNA Based Vaccines in Clinical Development
mRNA Vaccines in Phase IV Clinical Trials
mRNA Vaccines in Phase III Clinical Trials
mRNA Vaccines in Phase II Clinical Trials
EXHIBIT 2: COVID-19 Vaccines in Pipeline by Technology
EXHIBIT 3: COVID-19 Vaccine Technologies in Pre-Clinical Studies
VARIOUS VIRUS VARIANTS
Emergence of Delta Variant Sparks New Wave of Infections
Is South African Variant a Formidable Threat?
E484K Mutation Challenges Vaccine Developers
Rising Cases in South Africa & Other Countries
California Strain Emerges to be More Contagious and Deadly
Pfizer COVID-19 Vaccine Demonstrates Low to Modest Level of
Efficacy against South African Variant
Pfizer/BioNTech Trailing a Third Covid-19 Shot to Provide
Variant Protection
Moderna?s Variant-Specific Vaccine Candidate Ready for Clinical
Study
RECENT MARKET ACTIVITY IN THE COVID-19 VACCINE SPACE
Pfizer and BioNTech?s COVID-19 Vaccine Receives World?s First
Authorization
UK Clinches the First Position in the World to Approve Pfizer?s
Vaccine
After UK, US Gives Nod to Pfizer?s Vaccine
EU Approves Pfizer?s Vaccine
BioNTech to Scale up Vaccine Production to Fill Supply Gaps and
Support Vaccination Efforts in the EU
Novartis Inks Agreement with Pfizer-BioNtech to Support Covid-
19 Vaccine Production
FDA Approves Pfizer-BioNTech Vaccine in Kids aged 12 to 15
Years Age (May, 2021)
Moderna?s mRNA Vaccine Bags Approval from US FDA
Moderna Kick-Starts Inoculation in the US
FDA Approves Pfizer-BioNTech Vaccine in Kids aged 12 to 15
Years Age (May, 2021)
Moderna Begins Testing its Vaccine on Children Aged Below 12
Years (March, 2021)
Sanofi Plans on Acquiring Translate Bio; Increases mRNA
Technology Deployment Across Therapeutics Development And
Vaccines
BioNTech Announces Plans for Developing mRNA-based vaccine for
Preventing Malaria
CureVac COVID-19 Vaccine Disappointment
Setback in Covid Vaccine From CureVac Shows Inequality Among
mRNA Jabs
I-Mab Joins Hands with Chinese Biotech Players to Discover
Novel Oncology Therapeutics using mRNA & AI Techniques
Recent Market Activity
COMPETITIVE SCENARIO
BioNTech - A Pioneer in mRNA-based Vaccines and Therapies
List of BioNTech?s mRNA Candidates in Clinical Trials for Cancer
Moderna?s Ambitious Stride into Vaccine Development: From a
Novice to Know All
Moderna?s mRNA Prophylactic Vaccines
mRNA Cancer Vaccines
mRNA Intratumoral Immuno-Oncology
mRNA Systemic Secreted & Cell Surface Therapeutics
mRNA Systemic Intracellular Therapeutics
Sanofi Commences Clinical Trials of mRNA vaccine for Covid-19
mRNA as Promising Vaccine Technology Entices Startups to Join
the Bandwagon
Noteworthy Startups Exploiting mRNA Technology
Providence Therapeutics
pHion Therapeutics
eTheRNA immunotherapies & 20Med Therapeutics

2. FOCUS ON SELECT PLAYERS

3. AN INSIGHT INTO MRNA THERAPEUTICS
A Prelude to RNA Therapeutics
mRNA Therapeutics Market Perspective
MRNA Therapeutics Undergoing Clinical Trials
The Evolution of mRNA Therapeutics
mRNA Replacement Therapy
Cell Therapeutic Modalities integrating mRNA Approach
RNA and Cancer Treatment
mRNA and Medical Conditions
Research Trials involving mRNA Therapeutics
Delivery of RNA Therapeutics
Lipid-Based Nanoparticles
Polymer Nanomaterials
Silica Nanoparticles
Carbon and Gold Nanomaterials
N-Acetylgalactosamine (GalNAc)

4. MARKET TRENDS & DRIVERS
Rising Incidence of Coronavirus Cases Drives the Market Demand
EXHIBIT 4: COVID-19 Cases Worldwide by Country: As on July 26,
2021
EXHIBIT 5: COVID-19 Cases in the US by State: As on July 26, 2021
Increasing Prevalence of Infectious & Chronic Conditions to
Unleash Gains & Help mRNA Vaccines Market Gallop Ahead
mRNA Vaccines Development for Other Infectious Diseases and
Therapeutic Areas Gains Momentum
EXHIBIT 6: Worldwide Cancer Incidence: Number of New Cancer
Cases Diagnosed for 2012, 2018 & 2040
Flu
HIV
EXHIBIT 7: Global HIV Prevalence: Number of People Living with
AIDs (in Thousands) by Region for 2018
EXHIBIT 8: Number of AIDS-Related Deaths (in Thousands) by
Region for 2018
Aging Demographics Add to the Global Burden of Chronic
Diseases, Presenting Opportunities for the Market
EXHIBIT 9: Global Aging Population Statistics for the 65+ Age
Group in Million by Geographic Region for the Years 2019,
2025, 2035 and 2050
EXHIBIT 10: Elderly Population (65+ Years) as a % of Total
Population by Developed, Less Developed and Least Developed
Regions: 2019 & 2030
Increasing Healthcare Expenditure to Foster Market Growth
EXHIBIT 11: World Healthcare Expenditure (In US$ Billion) for
the Years 2017-2023
EXHIBIT 12: Healthcare Costs as a % of GDP by Country for the
Years 2020 & 2023
Consistent Increase in Risks and Threats from Infections Drive
Healthy Market Growth
EXHIBIT 13: Global Number of Deaths Caused Due to Communicable
Diseases (In 000s)
Regulatory Landscape for mRNA Vaccines
Regulatory Pathway Dealing with mRNA Vaccines
mRNA Vaccine Patent Scenario
The Best Route of Administration for mRNA Vaccines
CDC Study on Vaccine Effectiveness States mRNA Vaccines Offer
More Protective Benefits than other Vaccines (March, 2021)
mRNA CANCER VACCINES
Introduction
mRNA Vaccines And Their Role in Cancer Research
mRNA Vaccine Methodology for Cancer and Infectious Diseases
mRNA Vaccines to Make New Cancer Treatment Possible
mRNA Vaccines for Cancer
Preventive Cancer Vaccines
Challenges Involved
Clinical Trials
Cancer Vaccines Vs. Immunotherapies
Clinical Trials of mRNA Encoding Immunostimulants
mRNA Vaccines Vs. DNA Vaccines
Clinical Trials of mRNA Encoding TAAs
mRNA Vaccines Vs. Other Vaccines
Clinical Trials of mRNA Vaccines Encoding Neoantigens (Neo-Ag)
Personalized mRNA Vaccine
Clinical Overview of mRNA Cancer Vaccines
mRNA encoding Immunostimulants
mRNA vaccine encoding tumor-associated antigens
mRNA vaccine encoding Neoantigen, personalized vaccine
mRNA INFLUENZA VACCINES
Perpetual Evolution of Influenza Viruses Makes mRNA a
Fascinating Vaccine Platform
The Ability of mRNA Vaccines to Prevent Flu or Replace
Vaccination for Seasonal Flu
Clinical Trials for mRNA Vaccines
mRNA Vaccine as Game Changer for Flu Viruses Eluding
Conventional Vaccine Efforts
mRNA: A Next-Generation Vaccination Approach
Moderna Moves Ahead to Brew Novel mRNA Vaccines for Influenza &
Other Viruses
COVID-19 Vaccine Technology to Foster Development of Effective
Flu Shots
mRNA Vaccines Vs. Other Flu Shots
mRNA Technology, H/N Spike Proteins & Clinical Trials
mRNA Technology: A Suitable Candidate for Universal & Effective
Influenza Vaccines
Benefits & Limitations of mRNA Vaccines over Traditional Options
Benefits
Limitations
The Role of mRNA-based Vaccines in Preventing Sexually-
Transmitted Diseases
H1N1 Vaccines

5. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for mRNA Vaccines by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2021 through 2027 and
% CAGR

Table 2: World 6-Year Perspective for mRNA Vaccines by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets for Years 2021 & 2027

Table 3: World Current & Future Analysis for COVID-19 mRNA
Vaccine by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2021 through
2027 and % CAGR

Table 4: World 6-Year Perspective for Covid-19 mRNA Vaccine by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2021 & 2027

Table 5: World Current & Future Analysis for mRNA Cancer
Vaccine by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2021 through
2027 and % CAGR

Table 6: World 6-Year Perspective for mRNA Cancer Vaccine by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2021 & 2027

Table 7: World Current & Future Analysis for Other mRNA
Vaccines by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2021 through
2027 and % CAGR

Table 8: World 6-Year Perspective for Other mRNA Vaccines by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2021 & 2027

III. MARKET ANALYSIS

UNITED STATES
Current Vaccine Scenario
New Delta Variant Cases Cause Concern
US Buys Additional 200 Doses of Pfizer Vaccines for Children
and Booster Shots
US FDA Gives Nod to Pfizer and Moderna?s mRNA Vaccines
Moderna Supplies 100 Million more Doses of COVID-19 Vaccine to
the US Government
Lonza Announces Plans to Double Moderna COVID-19 Vaccine Output
in Switzerland
US Regulators Give Nod to Pfizer-BioNTech COVID-19 Vaccine for
Ages 12 to 15
Sanofi Joins Hands with Moderna to Produce COVID-19 Vaccines
for Global Supply
Market Analytics
Table 9: USA Current & Future Analysis for mRNA Vaccines by
Indication - Covid-19 Vaccine, Cancer Vaccine and Other
Indications - Independent Analysis of Annual Sales in US$
Million for the Years 2021 through 2027 and % CAGR

Table 10: USA 6-Year Perspective for mRNA Vaccines by
Indication - Percentage Breakdown of Value Sales for Covid-19
Vaccine, Cancer Vaccine and Other Indications for the Years
2021 & 2027

CANADA
Vaccination Gathers Steam Across Canada
Canada Grants Approval to Pfizer?s COVID-19 Shot for Use in
Children in 12-15 Years Age Group
Market Analytics
Table 11: Canada Current & Future Analysis for mRNA Vaccines by
Indication - Covid-19 Vaccine, Cancer Vaccine and Other
Indications - Independent Analysis of Annual Sales in US$
Million for the Years 2021 through 2027 and % CAGR

Table 12: Canada 6-Year Perspective for mRNA Vaccines by
Indication - Percentage Breakdown of Value Sales for Covid-19
Vaccine, Cancer Vaccine and Other Indications for the Years
2021 & 2027

JAPAN
Slow Rollout of COVID-19 Vaccines in Japan
Japan Ropes in Armed Forces to Expedite Vaccinations
Slow Vaccination Rates Affect Olympics
Vaccine Passports
Japan Inks Deal with Pfizer to Secure 50 Million Additional
Doses of COVID-19 Vaccine
Japan Pushes Shipments of Pfizer?s COVID-19 Shots to Vaccinate
Elderly
Takeda Obtains Approval for Moderna?s Vaccine
Market Analytics
Table 13: Japan Current & Future Analysis for mRNA Vaccines by
Indication - Covid-19 Vaccine, Cancer Vaccine and Other
Indications - Independent Analysis of Annual Sales in US$
Million for the Years 2021 through 2027 and % CAGR

Table 14: Japan 6-Year Perspective for mRNA Vaccines by
Indication - Percentage Breakdown of Value Sales for Covid-19
Vaccine, Cancer Vaccine and Other Indications for the Years
2021 & 2027

CHINA
BioNTech?s Shot to Become First Western COVID-19 Vaccine to
Secure Authorization in China
Market Analytics
Table 15: China Current & Future Analysis for mRNA Vaccines by
Indication - Covid-19 Vaccine, Cancer Vaccine and Other
Indications - Independent Analysis of Annual Sales in US$
Million for the Years 2021 through 2027 and % CAGR

Table 16: China 6-Year Perspective for mRNA Vaccines by
Indication - Percentage Breakdown of Value Sales for Covid-19
Vaccine, Cancer Vaccine and Other Indications for the Years
2021 & 2027

EUROPE
EU Urges Nations to Focus on COVID-19 Vaccine Sharing & Export
to Beat the Pandemic (May, 2021)
COVID-19 Vaccine Drive Gathers Pace in Europe after Initial Glitch
EU Approves Pfizer?s Vaccine
EU Obtains 1.8 Billion Doses of Pfizer-BioNTech COVID-19 Vaccine
European Agency Makes Changes to Ramp Up Supply & Manufacturing
Capacity of Pfizer & Moderna COVID-19 Vaccines
BioNTech to Scale up Vaccine Production to Fill Supply Gaps and
Support Vaccination Efforts in the EU
Market Analytics
Table 17: Europe Current & Future Analysis for mRNA Vaccines by
Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Million for Years 2021 through 2027 and % CAGR

Table 18: Europe 6-Year Perspective for mRNA Vaccines by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK and Rest of Europe Markets for Years
2021 & 2027

Table 19: Europe Current & Future Analysis for mRNA Vaccines by
Indication - Covid-19 Vaccine, Cancer Vaccine and Other
Indications - Independent Analysis of Annual Sales in US$
Million for the Years 2021 through 2027 and % CAGR

Table 20: Europe 6-Year Perspective for mRNA Vaccines by
Indication - Percentage Breakdown of Value Sales for Covid-19
Vaccine, Cancer Vaccine and Other Indications for the Years
2021 & 2027

FRANCE
France Suggests mRNA Vaccines for Second Coronavirus Shot After
AstraZeneca?s First Shot
Market Analytics
Table 21: France Current & Future Analysis for mRNA Vaccines by
Indication - Covid-19 Vaccine, Cancer Vaccine and Other
Indications - Independent Analysis of Annual Sales in US$
Million for the Years 2021 through 2027 and % CAGR

Table 22: France 6-Year Perspective for mRNA Vaccines by
Indication - Percentage Breakdown of Value Sales for Covid-19
Vaccine, Cancer Vaccine and Other Indications for the Years
2021 & 2027

GERMANY
Table 23: Germany Current & Future Analysis for mRNA Vaccines
by Indication - Covid-19 Vaccine, Cancer Vaccine and Other
Indications - Independent Analysis of Annual Sales in US$
Million for the Years 2021 through 2027 and % CAGR

Table 24: Germany 6-Year Perspective for mRNA Vaccines by
Indication - Percentage Breakdown of Value Sales for Covid-19
Vaccine, Cancer Vaccine and Other Indications for the Years
2021 & 2027

ITALY
Italy Plans to Produce mRNA Vaccines Domestically
Market Analytics
Table 25: Italy Current & Future Analysis for mRNA Vaccines by
Indication - Covid-19 Vaccine, Cancer Vaccine and Other
Indications - Independent Analysis of Annual Sales in US$
Million for the Years 2021 through 2027 and % CAGR

Table 26: Italy 6-Year Perspective for mRNA Vaccines by
Indication - Percentage Breakdown of Value Sales for Covid-19
Vaccine, Cancer Vaccine and Other Indications for the Years
2021 & 2027

UNITED KINGDOM
Market Analysis
UK Wins COVID-19 Vaccine Race with Approval of Pfizer-BioNTech
Vaccine
Moderna Modifies Supply Contract with UK to Deliver Additional
Doses of COVID-19 Vaccine
UK?s Independent Vaccine Deals
Market Analytics
Table 27: UK Current & Future Analysis for mRNA Vaccines by
Indication - Covid-19 Vaccine, Cancer Vaccine and Other
Indications - Independent Analysis of Annual Sales in US$
Million for the Years 2021 through 2027 and % CAGR

Table 28: UK 6-Year Perspective for mRNA Vaccines by Indication -
Percentage Breakdown of Value Sales for Covid-19 Vaccine,
Cancer Vaccine and Other Indications for the Years 2021 & 2027

REST OF EUROPE
Table 29: Rest of Europe Current & Future Analysis for mRNA
Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and
Other Indications - Independent Analysis of Annual Sales in US$
Million for the Years 2021 through 2027 and % CAGR

Table 30: Rest of Europe 6-Year Perspective for mRNA Vaccines
by Indication - Percentage Breakdown of Value Sales for
Covid-19 Vaccine, Cancer Vaccine and Other Indications for the
Years 2021 & 2027

ASIA-PACIFIC
INDIA
Second Wave of Covid-19 in India Attributed to Delta Variant
Pfizer Looks Forward to Make its COVID-19 Vaccine Available in
India
Cipla to Import Moderna?s COVID-19 Vaccine to India
Moderna, Pfizer Vaccines Less Effective against COVID-19 Mutant
Found in India
AUSTRALIA
Australia Eyes on Onshore mRNA-based Vaccine Production Capability
NEW ZEALAND
New Zealand Acquires Ultra-Cold Freezers to Store Pfizer?s
COVID-19 Vaccine
Market Analytics
Table 31: Asia-Pacific Current & Future Analysis for mRNA
Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and
Other Indications - Independent Analysis of Annual Sales in US$
Million for the Years 2021 through 2027 and % CAGR

Table 32: Asia-Pacific 6-Year Perspective for mRNA Vaccines by
Indication - Percentage Breakdown of Value Sales for Covid-19
Vaccine, Cancer Vaccine and Other Indications for the Years
2021 & 2027

REST OF WORLD
THE MIDDLE EAST
BAHRAIN
Bahrain Becomes the Second Country to Offer Emergency Use
Approval to Pfizer?s Vaccine
AFRICA
SOUTH AFRICA
New Virus Variant in South Africa Creates a Challenge
Highly Infectious COVID-19 Variant Spurs Countries to Impose
Travel Ban from South Africa
LATIN AMERICA
Mass COVID-19 Vaccination Campaigns Launched in Latin American
Countries
BRAZIL
Brazil Signs Deal to Buy Additional 100 Million Doses from
Pfizer/BioNTech
MEXICO
Mexico?s Cofepris Approves Emergency Use of Pfizer’s COVID-19
Vaccine
Market Analytics
Table 33: Rest of World Current & Future Analysis for mRNA
Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and
Other Indications - Independent Analysis of Annual Sales in US$
Million for the Years 2021 through 2027 and % CAGR

Table 34: Rest of World 6-Year Perspective for mRNA Vaccines by
Indication - Percentage Breakdown of Value Sales for Covid-19
Vaccine, Cancer Vaccine and Other Indications for the Years
2021 & 2027

IV. COMPETITION
Total Companies Profiled: 96
Read the full report: https://www.reportlinker.com/p06156075/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001